Evidence map›Paper›PMID 36969382›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)

Promoting diversity and overcoming publication barriers in Latin American neuroscience and Alzheimer's disease research: A call to action.

Mychael V Lourenco, Wyllians Vendramini Borelli, Claudia Duran-Aniotz, Eduardo R Zimmer, Shamyr Sulyvan de Castro

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. The momentum for dementia research in Brazil.Alzheimer's & dementia (New York, N. Y.)
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Mychael V LourencoInstitute of Medical Biochemistry Leopoldo de Meis Federal University of Rio de Janeiro Rio de Janeiro Brazil.
Wyllians Vendramini BorelliPharmacology and Therapeutics Research Program Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil.
Claudia Duran-AniotzLatin American Institute for Brain Health (BrainLat) Universidad Adolfo Ibáñez Santiago Chile.
Eduardo R ZimmerPharmacology and Therapeutics Research Program Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil.
Shamyr Sulyvan de CastroDepartment of Physiotherapy Federal University of Ceará - UFC Fortaleza Brazil.ORCID https://orcid.org/0000-0002-2661-7899
Universidade Federal do Rio Grande do Sul · BRAdolfo Ibáñez University · CLUniversidade Federal do Ceará · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a global health issue. Because AD is a condition demanding effective management, its socioeconomic burden is immense and threatens the health systems of both low- and middle-income (LMIC) and high-income (HIC) countries. However, while most of the HICs are increasing their budget for AD research, the situation is different in LMICs, and resources are scarce. In addition, LMIC researchers face significant barriers to publishing in international peer reviewed journals, including funding constraints; language barriers; and in many cases, high article processing charges. In this perspective, we discuss these disparities and propose some actions that could help promote diversity, and ultimately translate into improved AD research capacity in LMICs, especially in Latin American and Caribbean countries. HIGHLIGHTS: Researchers in low- and middle-income countries (LMIC) face increasing difficulties such as financial constraints, language barriers, and article processing charges.Publication fees, in particular, can be a significant barrier in the process of publication and equal access to scientific information.Publication fee equalization initiatives by publishing companies could reduce the scientific inequality that disadvantages researchers in LMICs.

Indexed as

Alzheimer's diseasearticle processing chargesfunding disparitiespublishing barriers

Identifiers

PMID36969382
PMCPMC10032204
OpenAlexW4360595879

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.